Skip to content

Prospective Observational Study of Combined Analysis of Proteomes and Transcriptomes of Hepatocellular Carcinoma after Incomplete Radiofrequency Ablation

Prospective Observational Study of Combined Analysis of Proteomes and Transcriptomes of Hepatocellular Carcinoma after Incomplete Radiofrequency Ablation

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055606
Enrollment
Unknown
Registered
2022-01-14
Start date
2022-01-17
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

before and after RFA:Nil

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative clinical diagnosis was patients with hepatocellular carcinoma who could obtain local radical curative effect through treatment; 2. Aged 18 to 80 years; 3. Clear consciousness and cooperation; 4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 3; 5. Liver function is grade A or B; 6. Expected survival more than 3 months; 7. Single tumor and tumor size < = 5.0 cm.

Exclusion criteria

Exclusion criteria: 1. Diffuse or large carcinomas; 2. There are vessels or other organs invaded; 3. Refractory ascites, bad fluid; 4. Severe coagulation dysfunction; 5. Recent history of gastrointestinal bleeding; 6. Failure of vital organs 7. Severe mental illness, severe heart, lungs and kidneys disease, etc; 8. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
proteomes;transcriptomes;immune cell changge;

Countries

China

Contacts

Public ContactLiao Rui

The First Affiliated Hospital of Chongqing Medical University

liaorui99@163.com+86 15922963763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026